{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:42:27Z","timestamp":1790790147415,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les H\u00e9patites Virales","doi-asserted-by":"publisher","award":["ECTZ 103985"],"award-info":[{"award-number":["ECTZ 103985"]}],"id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les H\u00e9patites Virales","doi-asserted-by":"publisher","award":["ECTZ 163186"],"award-info":[{"award-number":["ECTZ 163186"]}],"id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]},{"name":"FRM","award":["EQU202003010517"],"award-info":[{"award-number":["EQU202003010517"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s12072-022-10389-6","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T17:02:47Z","timestamp":1659632567000},"page":"1259-1272","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Diversity of the nucleic acid forms of circulating HBV in chronically infected patients and its impact on viral cycle"],"prefix":"10.1007","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct01953458","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jules","family":"Sotty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Bablon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bouchra","family":"Lekbaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9my","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Girier-Dufournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Langlois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Dorival","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Carrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Fontaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazim","family":"Sarica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Neuveut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Housset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Kremdsorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Schnuriger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2706-7371","authenticated-orcid":false,"given":"Patrick","family":"Soussan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,4]]},"reference":[{"issue":"67","key":"10389_CR1","first-page":"370","volume":"2017","author":"European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL","year":"2017","unstructured":"European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL. Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol 2017;2017(67):370\u2013398","journal-title":"J Hepatol"},{"key":"10389_CR2","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.virol.2015.02.031","volume":"479\u2013480","author":"C Seeger","year":"2015","unstructured":"Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology 2015;479\u2013480:672\u2013686","journal-title":"Virology"},{"key":"10389_CR3","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00798-18","volume":"92","author":"L BaiBai","year":"2018","unstructured":"Bai L, Zhang X, Kozlowski M, et al. Extracellular hepatitis B virus RNAs are heterogeneous in length and circulate as capsid-antibody complexes in addition to virions in chronic hepatitis B patients. J Virol 2018;92:e00798-18","journal-title":"J Virol"},{"issue":"3","key":"10389_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/v9030056","volume":"9","author":"J HuHu","year":"2017","unstructured":"Hu J, Liu K. Complete and incomplete hepatitis B virus particles: formation, function, and application. Viruses 2017;9(3):56","journal-title":"Viruses"},{"key":"10389_CR5","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3389\/fimmu.2016.00335","volume":"7","author":"T Kouwaki","year":"2016","unstructured":"Kouwaki T, Fukushima Y, Daito T, et al. Extracellular vesicles including exosomes regulate innate immune responses to hepatitis B virus infection. Front Immunol 2016;7:335","journal-title":"Front Immunol"},{"key":"10389_CR6","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1096\/fj.14-258715","volume":"29","author":"JG Pol","year":"2015","unstructured":"Pol JG, Lekbaby B, Redelsperger F, et al. Alternative splicing-regulated protein of hepatitis B virus hacks the TNF-alpha-stimulated signaling pathways and limits the extent of liver inflammation. FASEB J 2015;29:1879\u20131889","journal-title":"FASEB J"},{"key":"10389_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1172\/JCI8098","volume":"105","author":"P Soussan","year":"2000","unstructured":"Soussan P, Garreau F, Zylberberg H, et al. In vivo expression of a new hepatitis B virus protein encoded by a spliced RNA. J Clin Invest 2000;105:55\u201360","journal-title":"J Clin Invest"},{"key":"10389_CR8","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1086\/589623","volume":"198","author":"P Soussan","year":"2008","unstructured":"Soussan P, Pol J, Garreau F, et al. Expression of defective hepatitis B virus particles derived from singly spliced RNA is related to liver disease. J Infect Dis 2008;198:218\u2013225","journal-title":"J Infect Dis"},{"key":"10389_CR9","doi-asserted-by":"crossref","unstructured":"Kremsdorf D, Lekbaby B, Bablon P, et al. Alternative splicing of viral transcripts: the dark side of HBV. Gut 2021, 70:2373\u20132382","DOI":"10.1136\/gutjnl-2021-324554"},{"key":"10389_CR10","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jhep.2013.06.018","volume":"59","author":"J Bayliss","year":"2013","unstructured":"Bayliss J, Lim L, Thompson AJ, et al. Hepatitis B virus splicing is enhanced prior to development of hepatocellular carcinoma. J Hepatol 2013;59:1022\u20131028","journal-title":"J Hepatol"},{"key":"10389_CR11","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.jhep.2017.05.025","volume":"67","author":"M Duriez","year":"2017","unstructured":"Duriez M, Mandouri Y, Lekbaby B, et al. Alternative splicing of hepatitis B virus: a novel virus\/host interaction altering liver immunity. J Hepatol 2017;67:687\u2013699","journal-title":"J Hepatol"},{"key":"10389_CR12","doi-asserted-by":"crossref","unstructured":"Lim CS, Sozzi V, Littlejohn M, et al. Quantitative analysis of the splice variants expressed by the major hepatitis B virus genotypes. Microb Genom 2021;7","DOI":"10.1099\/mgen.0.000492"},{"key":"10389_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.virol.2012.05.008","volume":"431","author":"F Redelsperger","year":"2012","unstructured":"Redelsperger F, Lekbaby B, Mandouri Y, et al. Production of hepatitis B defective particles is dependent on liver status. Virology 2012;431:21\u201328","journal-title":"Virology"},{"key":"10389_CR14","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S0168-8278(02)00422-1","volume":"38","author":"P Soussan","year":"2003","unstructured":"Soussan P, Tuveri R, Nalpas B, et al. The expression of hepatitis B spliced protein (HBSP) encoded by a spliced hepatitis B virus RNA is associated with viral replication and liver fibrosis. J Hepatol 2003;38:343\u2013348","journal-title":"J Hepatol"},{"key":"10389_CR15","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00680-17","volume":"61","author":"AM Lam","year":"2017","unstructured":"Lam AM, Ren S, Espiritu C, et al. Hepatitis B virus capsid assembly modulators, but not nucleoside analogs, inhibit the production of extracellular pregenomic RNA and spliced RNA variants. Antimicrob Agents Chemother 2017;61:e0080-17","journal-title":"Antimicrob Agents Chemother"},{"key":"10389_CR16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/cid\/ciaa013","volume":"72","author":"MS Farag","year":"2021","unstructured":"Farag MS, van Campenhout MJH, Pfefferkorn M, et al. Hepatitis B virus RNA as early predictor for response to pegylated interferon alpha in HBeAg-negative chronic hepatitis B. Clin Infect Dis 2021;72:202\u2013211","journal-title":"Clin Infect Dis"},{"key":"10389_CR17","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1002\/hep.32018","volume":"74","author":"MG Ghany","year":"2021","unstructured":"Ghany MG, King WC, Lisker-Melman M, et al. Comparison of HBV RNA and hepatitis B core related antigen with conventional HBV markers among untreated adults with chronic hepatitis B in North America. Hepatology 2021;74:2395\u20132409","journal-title":"Hepatology"},{"key":"10389_CR18","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/jvh.13425","volume":"28","author":"A Goncalves","year":"2021","unstructured":"Goncalves A, Lemenuel-Diot A, Cosson V, et al. What drives the dynamics of HBV RNA during treatment? J Viral Hepat 2021;28:383\u2013392","journal-title":"J Viral Hepat"},{"key":"10389_CR19","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1093\/infdis\/jiv397","volume":"213","author":"L Jansen","year":"2016","unstructured":"Jansen L, Kootstra NA, van Dort KA, et al. Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos(t)ide analogues. J Infect Dis 2016;213:224\u2013232","journal-title":"J Infect Dis"},{"key":"10389_CR20","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1111\/liv.14606","volume":"40","author":"A Kaewdech","year":"2020","unstructured":"Kaewdech A, Tangkijvanich P, Sripongpun P, et al. Hepatitis B surface antigen, core-related antigen and HBV RNA: Predicting clinical relapse after NA therapy discontinuation. Liver Int 2020;40:2961\u20132971","journal-title":"Liver Int"},{"key":"10389_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12876-019-0966-4","volume":"19","author":"Y Liu","year":"2019","unstructured":"Liu Y, Jiang M, Xue J, et al. Serum HBV RNA quantification: useful for monitoring natural history of chronic hepatitis B infection. BMC Gastroenterol 2019;19:53","journal-title":"BMC Gastroenterol"},{"key":"10389_CR22","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1097\/MCG.0000000000001376","volume":"54","author":"Y Liu","year":"2020","unstructured":"Liu Y, Xue J, Liao W, et al. Serum HBV RNA dynamic and drug withdrawal predictor value in patients with chronic HBV infection on long-term nucleos(t)ide analogue (NA) therapy. J Clin Gastroenterol 2020;54:e73\u2013e82","journal-title":"J Clin Gastroenterol"},{"key":"10389_CR23","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1002\/hep.31616","volume":"73","author":"LY Mak","year":"2021","unstructured":"Mak LY, Cloherty G, Wong DK, et al. HBV RNA profiles in patients with chronic hepatitis B under different disease phases and antiviral therapy. Hepatology 2021;73:2167\u20132179","journal-title":"Hepatology"},{"key":"10389_CR24","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/hep.27381","volume":"61","author":"F van Bommel","year":"2015","unstructured":"van Bommel F, Bartens A, Mysickova A, et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology 2015;61:66\u201376","journal-title":"Hepatology"},{"key":"10389_CR25","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/jvh.13272","volume":"27","author":"MJH van Campenhout","year":"2020","unstructured":"van Campenhout MJH, van Bommel F, Pfefferkorn M, et al. Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg-positive chronic hepatitis B. J Viral Hepat 2020;27:610\u2013619","journal-title":"J Viral Hepat"},{"key":"10389_CR26","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jhep.2016.05.029","volume":"65","author":"J Wang","year":"2016","unstructured":"Wang J, Shen T, Huang X, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol 2016;65:700\u2013710","journal-title":"J Hepatol"},{"key":"10389_CR27","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000027433","volume":"100","author":"Y Xiang","year":"2021","unstructured":"Xiang Y, Yang Y, Chen P, et al. Analysis of serum hepatitis B virus RNA levels among HBsAg and HBsAb copositive patients and its correlation with HBV DNA. Medicine (Baltimore) 2021;100:e27433","journal-title":"Medicine (Baltimore)"},{"key":"10389_CR28","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1007\/s00535-021-01812-0","volume":"56","author":"Y Xie","year":"2021","unstructured":"Xie Y, Li M, Ou X, et al. HBeAg-positive patients with HBsAg < 100 IU\/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation. J Gastroenterol 2021;56:856\u2013867","journal-title":"J Gastroenterol"},{"key":"10389_CR29","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00075-20","volume":"58","author":"XQ Yu","year":"2020","unstructured":"Yu XQ, Wang MJ, Yu DM, et al. Comparison of serum hepatitis B virus rna levels and quasispecies evolution patterns between entecavir and pegylated-interferon MONO-treatment in chronic hepatitis B patients. J Clin Microbiol 2020;58:e00075-20","journal-title":"J Clin Microbiol"},{"key":"10389_CR30","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s12072-020-10015-3","volume":"14","author":"M Zhang","year":"2020","unstructured":"Zhang M, Li G, Shang J, et al. Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study. Hepatol Int 2020;14:212\u2013224","journal-title":"Hepatol Int"},{"key":"10389_CR31","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.cca.2019.10.049","volume":"501","author":"G Ma","year":"2020","unstructured":"Ma G, Lou B, Lv F, et al. HBcrAg, pg RNA and HBsAg dynamically supervise the seroconversion of HBsAg with anti-viral therapy: \u201cLoss of HBsAg\u201d maybe not a good end-point of anti-viral therapy. Clin Chim Acta 2020;501:264\u2013269","journal-title":"Clin Chim Acta"},{"key":"10389_CR32","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jhep.2020.01.028","volume":"73","author":"B Stadelmayer","year":"2020","unstructured":"Stadelmayer B, Diederichs A, Chapus F, et al. Full-length 5\u2019RACE identifies all major HBV transcripts in HBV-infected hepatocytes and patient serum. J Hepatol 2020;73:40\u201351","journal-title":"J Hepatol"},{"key":"10389_CR33","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1111\/jvh.12908","volume":"25","author":"J Wang","year":"2018","unstructured":"Wang J, Yu Y, Li G, et al. Natural history of serum HBV-RNA in chronic HBV infection. J Viral Hepat 2018;25:1038\u20131047","journal-title":"J Viral Hepat"},{"key":"10389_CR34","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12985-020-01471-2","volume":"18","author":"X Wang","year":"2021","unstructured":"Wang X, Chi X, Wu R, et al. Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment. Virol J 2021;18:4","journal-title":"Virol J"},{"key":"10389_CR35","doi-asserted-by":"publisher","first-page":"361","DOI":"10.17219\/acem\/131756","volume":"30","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Peng Y, Yuan H, et al. Serum hepatitis B virus ribonucleic acid and its influencing factors in chronic hepatitis B. Adv Clin Exp Med 2021;30:361\u2013367","journal-title":"Adv Clin Exp Med"},{"key":"10389_CR36","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12985-018-0994-7","volume":"15","author":"K Prakash","year":"2018","unstructured":"Prakash K, Rydell GE, Larsson SB, et al. High serum levels of pregenomic RNA reflect frequently failing reverse transcription in hepatitis B virus particles. Virol J 2018;15:86","journal-title":"Virol J"},{"key":"10389_CR37","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1002\/jmv.26529","volume":"93","author":"ML Wang","year":"2021","unstructured":"Wang ML, Liao J, Ye F, et al. Distribution and factors associated with serum HBV pregenomic RNA levels in Chinese chronic hepatitis B patients. J Med Virol 2021;93:3688\u20133696","journal-title":"J Med Virol"},{"key":"10389_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008945","volume":"16","author":"S Shen","year":"2020","unstructured":"Shen S, Xie Z, Cai D, et al. Biogenesis and molecular characteristics of serum hepatitis B virus RNA. PLoS Pathog 2020;16:e1008945","journal-title":"PLoS Pathog"},{"key":"10389_CR39","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/22221751.2022.2045874","volume":"11","author":"G Yu","year":"2022","unstructured":"Yu G, Chen R, Zheng S, et al. A standardized assay for the quantitative detection of serum HBV RNA in chronic hepatitis B patients. Emerg Microbes Infect 2022;11:775\u2013785","journal-title":"Emerg Microbes Infect"},{"key":"10389_CR40","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.jhep.2015.06.023","volume":"63","author":"L Riviere","year":"2015","unstructured":"Riviere L, Gerossier L, Ducroux A, et al. HBx relieves chromatin-mediated transcriptional repression of hepatitis B viral cccDNA involving SETDB1 histone methyltransferase. J Hepatol 2015;63:1093\u20131102","journal-title":"J Hepatol"},{"key":"10389_CR41","doi-asserted-by":"publisher","first-page":"7144","DOI":"10.3748\/wjg.v27.i41.7144","volume":"27","author":"S Garcia-Garcia","year":"2021","unstructured":"Garcia-Garcia S, Cortese MF, Tabernero D, et al. Cross-sectional evaluation of circulating hepatitis B virus RNA and DNA: different quasispecies? World J Gastroenterol 2021;27:7144\u20137158","journal-title":"World J Gastroenterol"},{"key":"10389_CR42","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jhep.2017.10.030","volume":"68","author":"J Wang","year":"2018","unstructured":"Wang J, Sheng Q, Ding Y, et al. HBV RNA virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-deficient. J Hepatol 2018;68:847\u2013849","journal-title":"J Hepatol"},{"key":"10389_CR43","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/hep.30844","volume":"71","author":"Y Liu","year":"2020","unstructured":"Liu Y, Liu H, Hu Z, et al. Hepatitis B virus virions produced under nucleos(t)ide analogue treatment are mainly not infectious because of irreversible DNA chain termination. Hepatology 2020;71:463\u2013476","journal-title":"Hepatology"},{"key":"10389_CR44","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02161-18","volume":"93","author":"Y Yao","year":"2019","unstructured":"Yao Y, Yang B, Chen Y, et al. RNA-binding motif protein 24 (RBM24) is involved in pregenomic RNA packaging by mediating interaction between hepatitis B virus polymerase and the epsilon element. J Virol 2019;93:e02161-18","journal-title":"J Virol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-022-10389-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-022-10389-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-022-10389-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T01:37:14Z","timestamp":1669513034000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-022-10389-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,4]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10389"],"URL":"https:\/\/doi.org\/10.1007\/s12072-022-10389-6","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,4]]},"assertion":[{"value":"2 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jules Sotty, Pierre Bablon, Bouchra Lekbaby, Jeremy Augustin, Morgane Girier-Dufournier, Lucas Langlois, Celine Dorival, Fabrice Carrat, Stanislas Pol, Helene Fontaine, Nazim Sarica, Christine Neuveut, Chantal Housset, Dina Kremsdorf, Aurelie Schnuriger and Patrick Soussan declare that they have no current financial arrangement or affiliation with any organization that may have a direct influence on their work. The ANRS CO22 HEPATHER cohort is sponsored and funded by INSERM\u2010ANRS and established in collaboration with Association Fran\u00e7aise pour l'Etude du Foie\u00a0(AFEF).\u00a0The cohort received supports from Agence Nationale de la Recherche (ANR), Direction G\u00e9n\u00e9rale de la Sant\u00e9 (DGS), MSD, Janssen, Gilead, Abbvie, BMS, and Roche.\u00a0The public\/private partnership is built in total transparency through a specific contract. The pharmaceutical companies are not involved in scientific decisions. The sponsor did not contribute to the study design and drafting of the study. The sponsor played no role in data collection, data analysis or data interpretation. The other funding sources played no role in study design, data collection, data analysis, data interpretation, or drafting the study. CF had full access to all data in the cohort study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal research"}},{"value":"Written informed consent was obtained from each patient before enrolment. HEPATHER protocol was conducted in accordance with the Declaration of Helsinki and French law for biomedical research and was approved by the \u201cComit\u00e9 de Protection des Personnes Ile de France 3\u201d Ethics Committee (Paris, France) and the French Regulatory Authority.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All the authors agreed with the content and gave explicit consent to submit this work.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}